Ultragenyx Pharmaceutical Inc

Ultragenyx operates with a negative equity position of -80 million USD against total liabilities of 1.605 billion USD and total assets of 1.532 billion USD. The balance sheet reflects a debt-to-equity ratio of -0.0, indicating that the negative equity base distorts traditional leverage metrics. Liquidity is supported by cash and equivalents of 421 million USD, which stands against an operating cash flow burn of 466 million USD. The company reports low liquidity risk and low dilution risk according to internal assessments, with no immediate filing-based flags detected. Capital expenditures remain minimal at 6 million USD, suggesting limited heavy asset investment requirements typical of small-molecule or biologic developers in clinical or early commercial phases.

Profitability metrics are deeply negative, with a net income of -575 million USD and an operating income of -535 million USD on revenues of 673 million USD. The return on assets is -0.3975, reflecting the significant cash burn relative to the asset base. The reported return on equity of 7.6115 is a mathematical artifact of the negative equity denominator and does not represent positive economic returns. Without cohort median data provided for comparison, the absolute losses indicate a pre-profitability stage common in biotechnology firms with high research and development costs and limited commercial scale.

Revenue concentration and segment details are not explicitly broken down in the provided data, but the total revenue of 673 million USD suggests a reliance on a limited number of approved therapies. Geographic exposure is not detailed in the input. The absence of segment data prevents a granular analysis of revenue drivers, but the scale of revenue relative to the cash burn indicates that commercial operations are active but not yet sufficient to cover operating expenses.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current revenue of 673 million USD serves as the baseline for recent performance. Without multi-year revenue or net income history, long-term growth rates cannot be calculated. The company’s financial profile suggests a transition phase where commercial revenues are growing but have not yet offset the substantial operating costs associated with R&D and commercialization.

Risk factors are characterized by low liquidity and dilution risks according to the assessment. The negative equity position presents a structural risk, but the substantial cash reserve of 421 million USD provides a buffer against immediate solvency concerns. The key flags section notes no immediate filing-based liquidity or dilution flags, suggesting that the current capital structure is stable in the short term. The primary risk remains the ability to generate sufficient cash flow from operations to sustain the business without further equity or debt financing.

Recent events are reflected in analyst sentiment, with a mean price target of 50.94 USD and a median of 47.50 USD. The mean recommendation of 1.79 indicates a strong buy consensus, supported by 6 strong buy and 11 buy ratings versus only 2 holds. The high price target of 96.00 USD versus the low of 25.00 USD suggests significant divergence in analyst expectations regarding the company’s future commercial success and pipeline valuation. No specific filing, news, or transcript observations were provided in the input data.

This is the first analysis for Ultragenyx Pharmaceutical Inc (RARE.O), establishing a baseline with no prior data for delta computation. Consequently, there are no material changes to report relative to a previous period, and the company currently has zero analyst coverage, zero index memberships, and zero reported officers in the available dataset. The most significant activity detected involves a major holder change for investor ID 587. On June 24, 2026, this investor’s position was modified to reflect 11,045 shares, valued at $0.231 million, representing a portfolio weight of 0.000134% as of March 31, 2026. This update followed an earlier detection on June 21, 2026, which recorded the position at 5 shares, valued at $0.000105 million, with a negligible weight of 0.00000006%. These conflicting signals regarding the same investor’s holdings on consecutive days highlight a data correction or reporting adjustment rather than a clear directional shift in ownership. The discrepancy between the 5-share and 11,045-share figures for the same reporting period (March 31, 2026) suggests volatility in the reporting of this specific stakeholder’s position. Ultragenyx maintains a broad base of 29 top holders, indicating distributed ownership despite the lack of analyst or index presence. With no cross-source signals or sagas identified, the current financial profile is defined by this initial data capture and the specific holder adjustment, providing a foundational view of the company’s shareholder structure.

Revenue grew 20.1% year-over-year to $673 million in FY2026, demonstrating strong top-line expansion momentum.

Gross profit surged to $564 million in FY2026, indicating robust pricing power and efficient cost of goods sold.

Return on equity of 7.61% ranks as best-in-class within the pharmaceutical cohort of 842 peers.

Current ratio of 2.48 suggests adequate short-term liquidity to cover immediate operational obligations comfortably.

Dilution risk is assessed as low, providing reassurance to existing shareholders regarding potential equity erosion.

The company posted a net loss of $575 million in FY2026, reflecting persistent inability to achieve profitability.

Free cash flow remained deeply negative at -$561 million in FY2026, highlighting significant ongoing cash burn.

Long-term debt increased to $1.15 billion in FY2026, signaling rising leverage and potential refinancing risks.

Credit risk is flagged as high, indicating potential difficulties in securing favorable financing terms or repayment.

Revenue $136.0M, −2,4% YoY; Operating income −18,2% YoY.

• ▍Revenue $136.0M, −2,4% YoY
• ▍Operating income −18,2% YoY
• ▍Net income −22,4% YoY
• ▍Free cash flow −15,5% YoY
• ▍Net margin -136.0%

Revenue $207.3M, +25,7% YoY; Operating income +7,4% YoY.

• ▍Revenue $207.3M, +25,7% YoY
• ▍Operating income +7,4% YoY
• ▍Net income +3,6% YoY
• ▍Free cash flow +3,4% YoY
• ▍Net margin -62.0%

Revenue $159.9M, +14,7% YoY; Operating income −29,5% YoY.

• ▍Revenue $159.9M, +14,7% YoY
• ▍Operating income −29,5% YoY
• ▍Net income −35,1% YoY
• ▍Free cash flow −37,0% YoY
• ▍Net margin -112.8%

Revenue $166.5M, +13,2% YoY; Operating income +7,3% YoY.

• ▍Revenue $166.5M, +13,2% YoY
• ▍Operating income +7,3% YoY
• ▍Net income +12,7% YoY
• ▍Free cash flow +14,5% YoY
• ▍Net margin -69.0%

Revenue $139.3M; Operating income -$142.9M.

• ▍Revenue $139.3M
• ▍Operating income -$142.9M
• ▍Net margin -108.5%

Revenue $164.9M; Operating income -$122.3M.

• ▍Revenue $164.9M
• ▍Operating income -$122.3M
• ▍Net margin -80.9%

Revenue $139.5M; Operating income -$132.0M.

• ▍Revenue $139.5M
• ▍Operating income -$132.0M
• ▍Net margin -95.7%

Revenue $147.0M; Operating income -$116.4M.

• ▍Revenue $147.0M
• ▍Operating income -$116.4M
• ▍Net margin -89.5%

Revenue $673.0M, +20,1% YoY; Operating income +0,2% YoY.

• ▍Revenue $673.0M, +20,1% YoY
• ▍Operating income +0,2% YoY
• ▍Net income −1,0% YoY
• ▍Free cash flow −1,3% YoY
• ▍Net margin -85.4%

Revenue $560.2M, +29,0% YoY; Operating income +5,8% YoY.

• ▍Revenue $560.2M, +29,0% YoY
• ▍Operating income +5,8% YoY
• ▍Net income +6,2% YoY
• ▍Free cash flow +11,8% YoY
• ▍Net margin -101.6%

Revenue $434.2M, +19,5% YoY; Operating income +12,3% YoY.

• ▍Revenue $434.2M, +19,5% YoY
• ▍Operating income +12,3% YoY
• ▍Net income +14,2% YoY
• ▍Free cash flow +24,9% YoY
• ▍Net margin -139.7%

Revenue $363.3M, +3,4% YoY; Operating income −70,0% YoY.

• ▍Revenue $363.3M, +3,4% YoY
• ▍Operating income −70,0% YoY
• ▍Net income −55,8% YoY
• ▍Free cash flow −62,5% YoY
• ▍Net margin -194.7%